Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification
This article was originally published in The Pink Sheet Daily
Executive Summary
Jeremy Levin, who left Bristol-Myers Squibb on Jan. 1, will succeed outgoing Teva CEO Shlomo Yanai in May, as the Israeli generics giant seeks to increase its emphasis on branded drugs.
You may also be interested in...
New Teva CEO’s Initial Priorities Are Manufacturing, Copaxone, R&D
Teva’s new CEO, Jeremy Levin, has been emphasizing manufacturing efficiency, global compliance and a more focused R&D structure in initial comments to Wall Street.
Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?
The bench trial in Teva Pharmaceutical USA Inc.'s Copaxone (glatiramer) patent infringement suit against Mylan Pharmaceuticals Inc. and Sandoz Inc. concluded on Sept. 21 and the parties now await a decision by the judge. If Teva is successful, it may end up asking itself what a victory in this patent battle would cost in the broader war on biosimilars.